Filed: 11/13/2024ACC: 0000950123-24-011277
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 11 equity positions with a total reported market value of $498.73M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
11
Positions
$498.73M
Total AUM (reported)
27.72M
Total Shares
Allocation by class
COMMON STOCK$444.52M89.1%
COMMON SHARES$54.21M10.9%
Portfolio Concentration
Top 3$337.26M67.6%
4–10$158.95M31.9%
11–25$2.53M0.5%
Top 3 weight
67.6%
Top 10 weight
99.5%
Voting Authority Distribution
Total shares with voting rights: 27.72M
Sole
Full voting authority
27.72M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole11
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings11
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$195.97M
39.29%
Sole
2.35M
Shared
0.00
None
0.00
Zenas BioPharma, Inc
SOLEShares4.91M
TypeSH
Market value$83.10M
16.66%
Sole
4.91M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$58.19M
11.67%
Sole
4.01M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares1.05M
TypeSH
Market value$49.28M
9.88%
Sole
1.05M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$35.11M
7.04%
Sole
6.53M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares2.02M
TypeSH
Market value$24.42M
4.90%
Sole
2.02M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$20.93M
4.20%
Sole
1.96M
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$15.07M
3.02%
Sole
3.33M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares375.33K
TypeSH
Market value$9.20M
1.84%
Sole
375.33K
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$4.94M
0.99%
Sole
747.75K
Shared
0.00
None
0.00
KALA Bio, Inc.
SOLEShares443.66K
TypeSH
Market value$2.53M
0.51%
Sole
443.66K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $195.97M 39.29% | 2.35M | 0.00 | 0.00 |
Zenas BioPharma, IncSOLE | Common Stock | 4.91M | SH | $83.10M 16.66% | 4.91M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $58.19M 11.67% | 4.01M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 1.05M | SH | $49.28M 9.88% | 1.05M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $35.11M 7.04% | 6.53M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 2.02M | SH | $24.42M 4.90% | 2.02M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $20.93M 4.20% | 1.96M | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $15.07M 3.02% | 3.33M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 375.33K | SH | $9.20M 1.84% | 375.33K | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $4.94M 0.99% | 747.75K | 0.00 | 0.00 |
KALA Bio, Inc.SOLE | Common Stock | 443.66K | SH | $2.53M 0.51% | 443.66K | 0.00 | 0.00 |